MUC16/CA125 is a tumor marker currently used in clinics for the follow-up of patients with ovarian cancer. However, MUC16 expression is not entirely restricted to ovarian malignancies and has been ...

A peak at phase 1 data of ubamatamab, a bispecific antibody targeting MUC16 and CD3, showed that it held promise among some of the sickest patients. Among participants who received at least one ...

Mutational analysis of key genes in patients from the Kazakh population with early onset of breast cancer. Discovering HPV16 and HPV18 infection status and cancer gene variations in cervical cancer ...

Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading its approved product and licensing antibody-drug conjugates (ADCs) for ...

Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include ...